-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Eu/FW74HSo5BB1gAcSPYHwCmqRF/lFFiqUksD+rDxD9uvCT/SGlJLPWe5kiQmSMs
 ffxMlcmNdT5hzgtlGM8fjA==

<SEC-DOCUMENT>0000950123-09-008010.txt : 20090713
<SEC-HEADER>0000950123-09-008010.hdr.sgml : 20090713
<ACCEPTANCE-DATETIME>20090505153816
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-09-008010
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20090505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><IMG src="y76724c1y7672401.gif" alt="(NOVOGEN LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">May&nbsp;5, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">U.S. Securities and Exchange Commission<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Re:</TD>
    <TD>&nbsp;</TD>
    <TD>Novogen Limited<br>
Form&nbsp;20-F/A for the fiscal year ended June&nbsp;30, 2008<br>
File No.&nbsp;000-29962</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is the response of Novogen Limited (the &#147;Company&#148;) to the comment set forth in
the letter, dated April&nbsp;23, 2009 (the &#147;Comment Letter&#148;), from the staff (the &#147;Staff&#148;) of the U.S.
Securities and Exchange Commission (the &#147;SEC&#148;) with respect to the Company&#146;s Annual Report on Form
20-F/A for the fiscal year ended June&nbsp;30, 2008 (File No.&nbsp;000-29962).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is the Staff&#146;s comment in italics followed by the Company&#146;s response.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><I>Item&nbsp;4. Information on the Company, page 15</I></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Business Overview, page 15</I></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><I>Licensing Arrangements, page 24</I></U>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>1. We note that in your response to comment 1 of our comment letter dated February&nbsp;24, 2009, you
have requested to include your proposed disclosure regarding the Patent License Agreement with
Archer Daniels Midland Company in your Annual Report on Form 20-F for the fiscal year ending June
30, 2009 rather than amend your Form 20-F for the fiscal year ended June&nbsp;30, 2008. We have
reviewed your proposed disclosure in connection with the application for confidential treatment of
certain portions of the agreement and the related amendment which you submitted on March&nbsp;23, 2009.
It appears that the annual minimum payments you receive under this agreement are material to the
company. Accordingly, please revise your proposed disclosure to include the guaranteed annual
minimum payments set forth in Article&nbsp;3.01(b)(vii) through Article&nbsp;3.01(b)(xiii) of the Amendment
to the Patent License Agreement. Please also include a general description of the schedule of
royalty payments that clearly discloses that the amount of royalties owed will adjust as a
percentage of sales of related products as the amount of such sales increase. Your disclosure
should give investors a general idea of how this adjustment works.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Response: </B>The following reflects the revised disclosure requested by Comment 1. The Company
respectfully requests that it be permitted to include the following disclosure in its Annual Report
on Form 20-F for the fiscal year ended June&nbsp;30, 2009 rather than amend its Annual Report on Form
20-F for the fiscal year ended June&nbsp;30, 2008 to include such disclosure.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1997, the Company granted an exclusive royalty-bearing license, with the right to grant
sublicenses, to Protein Technologies International, then a subsidiary of Ralston Purina Company
(&#147;PTI&#148;), covering three of the Company&#146;s patent applications (and U.S. patents arising from such
applications) for the development and commercialization of prescription and non-prescription drug
products and dietary health supplements in which the biologically active component is derived from
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">soy and consists of at least one isoflavone covered by one of the licensed patent applications (or
U.S. patents arising from such applications). The geographical territory of the license is
worldwide, with the exception of Australia and New Zealand. In 1997, Dupont acquired PTI and PTI
subsequently changed its name to Solae LLC (&#147;Solae&#148;) in connection with a joint venture that it
entered into with Bunge Ltd. In 2004, the parties amended the license to revise the schedule of
minimum annual payments and to provide for payment to be made by Solae to the Company in the event
that Solae sells its isoflavone drug program. The license was transferred to Archer Daniels
Midland Company (&#147;ADM&#148;) in 2005. U.S.
patents have been issued for all three patent applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the transfer, ADM assumed the rights and obligations formerly held by
Solae, including the obligation to make minimum annual payments and royalty payments to the
Company. Notwithstanding the transfer of the license agreement, Solae remains obligated to make
payment to the Company in the event that Solae sells its isoflavone drug program. The license
agreement will terminate upon the expiration or invalidation of the last of the patent applications
and/or patent rights that it covers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company received minimum annual payments from ADM of U.S. $1,250,000 and U.S. $1,320,000
in the fiscal years 2007 and 2008, respectively. ADM is also required to make the following future
minimum annual payments to the Company:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>U.S. $1,430,000 due by December&nbsp;31, 2009;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>U.S. $1,540,000 due by December&nbsp;31, 2010;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iii)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>U.S. $1,670,000 due by December&nbsp;31, 2011; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(iv)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>U.S. $2,000,000 by December&nbsp;31, 2012 and annually thereafter for so long as the agreement
effect.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual royalties payable under the terms of the agreement are computed at various
percentages of ADM&#146;s cumulative net sales of prescription and non-prescription drug products and
dietary health supplements covered by the licensed patents. ADM must pay the Company a certain
percentage of its cumulative net sales of the covered products as annual royalties until the
cumulative net sales reach a certain dollar amount. Thereafter, as the cumulative net sales
increase to certain specified dollar amount tiers, the percentage payable as royalties decreases
with each tier. In connection with agreement, the Company received royalty payments from ADM of
A$1.4&nbsp;million and A$1.7&nbsp;million in fiscal years 2008 and 2007, respectively.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">***
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In response to the Staff&#146;s Comment Letter, the Company has filed an Amended Application for
Confidential Treatment with respect to certain portions of the (i)&nbsp;Patent License Agreement, dated
as of November&nbsp;13, 1997, by and among Novogen Limited, Novogen Research Pty Limited, Novogen Inc.
(the &#147;Novogen Group&#148;) and Protein Technologies International Inc. and (ii)&nbsp;Amendment to the Patent
License Agreement, dated as of June&nbsp;21, 2004 by and among Novogen Limited, Novogen Research Pty
Limited, Novogen Inc. and Solae LLC (formerly known as Protein Technologies International Inc.)
(the &#147;Amendment&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Company&#146;s Amended Application for Confidential Treatment, the Company
filed Amendment No.&nbsp;2 to its Annual Report on Form 20-F/A for the fiscal year ended June&nbsp;30, 2008
on May&nbsp;5, 2009. The purpose of Amendment No.&nbsp;2 is to replace the version of the Amendment
previously filed as Exhibit&nbsp;4.11 to Amendment No.&nbsp;1 with a new version in which certain of the
information previously redacted (specifically, certain of the minimum annual payments set
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">forth in Article&nbsp;3.01(b)(vii) through Article&nbsp;3.01(b)(xiii)) is now included at the request of
the Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is responsible for the adequacy and accuracy of the disclosure in
the filings;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Staff comments or changes to disclosure in response to Staff comments do not
foreclose the SEC from taking any action with respect to the filing; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company may not assert Staff comments as a defence in any proceeding
initiated by the SEC or any person under the federal securities laws of the United
States.</TD>
</TR>

</TABLE>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Sincerely<BR>
<BR>
NOVOGEN LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ David Seaton
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">David Seaton&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y76724c1y7672401.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y76724c1y7672401.gif
M1TE&.#EAQP!+`.8``+.QKME6=^>MN=I)9>GHY=JJLOGX]_SR].JWPN)+;?KZ
M^;-F<?WX^D5S:?S\_'9R</S]^/C\^?K]_.67I_7U\]>7H?C;XNO`R-?9U?;4
MV\O)QMF(F/ON\<=5;<=E=_[Z^__\_.6+F,E;<]-YBOWU]_7Z^#UK8_/,TH>$
M@\+`OM5C>=R1G?KF[=53:_OK[8!]>_7Y]./BX-Q2</'Q[YJ7E<MWA7.1A$%N
M9]5K@/W^_M)07O[^^^1NAME-;DU.3>?;V-)29?W^^_#%SM_"P]Y[D/[]_9NO
MIXVHG?KBY\S7R_W\_>K,SM/1SO/J[]B!CKG-Q._W],QK@:)Z>[2\N-Q/9DYS
M;$IY;\Y+9,Z+E%=W<,-P?8^+B=O>V=_JY9^>G/3@X>SN[&>!>?;FY]%8;_G[
M^\-?;MY@>\76SU1L:3`T,\J`C$AF7:BFHMI;=-=RB(*=CH24C&!;6962D/?W
M]M!.;NA=?=UAE=)_E\I97S=%1>"AJ\Y?=&QG9?_^_O[^_O___R'Y!```````
M+`````#'`$L```?_@'^"@X2%AH>(B8=^?PH.C(J1DI.4E9:7F)F:FX9^CT4S
MD)RCI*6FIZB7#JLI"JFOL+&RLX5^?@H/#K2[O+V^B7Y%#@]<?GU]MK_*R\R<
MGA\E-E,4'Q]%$LW9VMN=9!\P;V$S"A\.V-SHZ;^WT$=H7F0&Y>KT];(2(`9'
M65E=#M7V`@H<Y2<""`5&JF2!TZ4(B!PY_B0;2+$B(C\Y'.R84J7*&C@S/DB(
M6*2(Q9,H)3KH\Z1*`Q-HGI20,#*ES8HY\)VQTJ"!E3!/(M`T=K-H/0?>,(3Q
MV>!&F"0P<A`U2K72,4''^EC*>I404@9<;/2\T:#*4S+!CMG2ZDS4LF1=_S'%
M)<56*UM)4D&`..:PB%2O$?_\Q5JR,$V:$$!(^`#F3=F>96U@(/=A1P0'(!1!
M@##XSUP))12I#0*ADH0@J'<H(H/-8:(^AV,?WNMGQXZ:.0755IT(M3&3GCW?
M592WB"V'?3H+#NQ6N%J($(/X_0#E2$?(5K)()G?;=>\@;J\RPG@.4=8=02H%
MD3H1D80B?>`7NIL<NGV(:FW_A:@[OB);OQ$R522_8205?.WQQ96```93F'%_
M,#"'$5;PY%.%:-B0A`.%*?%:5H(,AI&#P%UDUW"BZ568(BJB&!Q67,68G#'H
MP:<51,;X]Z%6;HFB'"(YU61('RHB2(A]?>D%PO]T9#Q1X9,5^F1#%SE8XZ%Y
M);$UTG@2!*,7<3!20F21BGRPI"0R<M6E<8F!`,E(\66VHV`AYNB'!&0$=LB-
M1:"VWH">N:D;38%QA9%$MH@D#!=/]A0E3W!`\8$2Y2T""7E2B6?+2.P=26AS
M!-K"GVX`0M3E6BBREULB[RV)#T:HL:;;?XS0)(@#2O051`1_-1>?'Q#LP``#
M.T"0UB#(?+J*<2!4XZP$$0@E`:7"=)&%3S=DJ^T-54QA@#F*<.K'0^:L5!*T
M$9#!H4,`2G28K)/X009K-)443(,YI1M!'PP4TN4'GL@F&V;6=`GM9C/ENQH9
M?T0KB!(D<'"`Q`KH.9__5D&0P`(+!T`01%QW1EME-1&S8,')2'!L`*]D/%2$
M$E#84.$-)FS;4Q88E&!Q+7DJP0`)#%R30Q\%DQ'!!R20<(`+'#!]`-"3KDJ@
M`](ZH$#2!SR=-=0Y&.U'OX20,RP#"I1=]F9H,U!-P-%"8``YE$:@2`G_O"T(
M`T-@@<4*%7RQ)*@2Y6#`$"NL@,`'?T`X*)X_NY!!`5C4H,7D6M10@1`LD&"F
M!+B2D1!/VV;;0!9A=%$ISTI\@8``0Y``T<M%*&``"18(H0<6:E2.A1X"9.`"
MV;K0*I$"#!Q0NP!Z5%`X[PB<D,$!##B06"$<9""$$"=DK_WVSA^0P\NL*;`$
M__8G6*"$W*P:;P$2C#!0@`<=J%"&``=(=,@J"N@APA@KD/"(*/$A0Q$.((0-
M>*`,>^A`!T3`0!%TH`QJ0``2%*6$$ISA6I!I"LUZ4@4`H`]()'B?""K`@6OX
MQ0$DR(`>M%"&!>ZA@7M0010V(`0.R"D1Q@D&!TZ@AQK`CX$+5&`9HE"#"0B!
M!+8IQ!+4$`4<1,$#4(RB%-7P!74QX'LNT`(4HT#"TQ7"`4NTG$E(H`<9)"`!
M,L#!$A3`")`AQ0`3"(`,0B"2SOBA&F(H0!3H0(<>R*`./`BD&=J0@`'0001W
M^((!7N8`,"R%+&,1'5G"P(1VA2D82!A!"V1P`1(H@/\U)2`!`MP0@!;(\8]U
M2*4,>M"#,2R@;TJX2XY(Q2\"K"`*'>BC#/ZX2S3V@`Y7H$,-EK"K0EP`!P'P
M8R]9><8SRF`$%K#B'5E0!E8&8`^':U=S0"`$#[0A!+J`8P\2T,H$;(`%>;)&
MB/#T`05,0`8M6(%(:F,@/+%@!2J@`Q#VH(8"9"!E2,@`X?;0@BL`@0@GB-X`
MWP`ZFMFL+$>8@S!L@1DE<*@$%Q@#$%30!`88@&XN$(`9_"@"-U1``,ZSGA[N
M,`:-CH$(&?#?][XWHB+L@`,7<$(+Z+!`DQ9```BX@``J$#D/T"&12!'0!<RP
M2BQ4X*E/W8!4I5H`,0@#5TK_:$(I@=""%A#!`H_016D(`8*,SC&<$QCG&#J0
M@#8(('J/")$Y/A"!=\93,7W8040RP@$][`&>*IB`!4B0*Y/X00DN&.48=``$
M:'X@!PQPDA5H5C-M88<)N#+.8BB5@SE,H`5C`"<#YD4"`8B`"G38PPI.X`*@
MX>H#!V"!'KS9`BK<P0)!HY9?[IC8/0#A"B(80>^>IC:2.4X`PG5=\'0C!#,,
MH`XQ31K6LD9=,_E%"5D-`!"`,`8JC$$/UI#*6)%E5G#^`8YFY(%.>X"##-11
M.,*@JUU7@-<@?.(#%XA"*7$@`!<\#1L`<L"P,N`$C7:@`BR``&/"T%#+6L$$
M/8'#_QS"BQD3BL$-`]C#!910#@9<H(5CB`+]@,8`SN2`P[#-@"83<.`#."('
MK@+!`02`AQ9D>`6#-<"PP@N"GQ7/OYLID40NT(8!F,$"?D*-V<HVK,P<-KM=
M'<,5VB"")02MQX4H0D:I$(+2P#$`YA2"&_RX`1?P2B*,E"\\Z2N!/@2!<Q_X
M@A/HD``5((`#:NO:(#`2+0-DP`W<+0,"_!<!(V3!H9"\P8.SE04N,*"P()CK
M4GO@!/8%PP(C^.7\#E`-TD2+4SEPVPF(D``Z")H$(Q$&&1BP!`^8,0$30`(#
M(A`:\D!K/<*`0+2"@+@]9U0'9D`"VA!6@F*70"\\PJY6-_\9@C%3`0M(<%.O
M!Z'E[FX`K<G<``<$T`89C.&MT`D&KNI*A;NV&0*K""$A>S`!#J`[2'LN`AF*
M?0`$=.`*`W#"%SBC%`V*KJ$^,0*'(5"2G)!@`ST(0`$8`!L&",",+4#P:70M
MLHS0A&H,0$``!G`%?>>I#])S@1-T0$XBN.`#$"@!%.0Z$FB!L@3[`IMNB+Q1
M,2A)+[;!.;+_@-5ETZ%Y>_"N'CC@@)U5FPI.P'8/-L``)&Q@#`%P0P88@*[X
MUG7->/6$$EB@21FH(`,*&$I[)$+URW"`"%=(P!Z&4((/4``.:VA*S;`U]P:$
M@0`@@,"T5F&!/=0Y`P*4`!)(307_#\14"?8M>H-L0?42W),*&;Z``Z13)03@
M`?)1R$"NX(WF')HJ!V_6T<S;T`(<V/SF9JK&7MCR9*T"H0.=G``0$H"#"R@@
M-&3=LGF_O'3B9:`&=!C#!%A0A'3!^>KF/L:T,A#T,6#A`$+)E)#[0%C6?$#C
M"8BXVQ@`@#3XFRS_'IT&2J!7BV9\##(H\WN*(`05#``/%3@`A]L5'QL1K8+B
MD\$`@*`'!@1!"7[``2,W`!U0``>P)=C%%\B&#!#Q-WZ0'KY&>CP@!JRQ"A+@
M"*OP00^37=RU!&2`:=FG!B2@@7]05MVU>W$D`RN@``,D``3U;23`&D*A9LEW
M)]=76VM7_Q`1P1>$P"\/,1)(@`,#0`4C0`X*,`-P<"TF`#H9U!-'``6W@44Z
M-0874`Z\I@>U508GL`K3YAE9<@R3<AH'P`-4@'0N``&YD@$J@%I1@`2L,33-
MHH"KQQ9+@@P0*`@[T%Q4$&P"$QN%H&S:!01+$`$>1GHJ4``&4`@FR&5HM4DK
M\"T.@`1.``1T,`*:=PW_@'QLA@S>4`$R4'@N4"RLUR.Y(A@2<``(YW4<4`X*
MP`7\X!+9$B5C,27FD!$G@`-4@`-(P"$9LP$R``0X\`4P=T.S0FW&$03B1'L9
M`![75V0=L`*CM0,\4B*_,A$0DE=*Q51U8#[8A5VK8%&G`XC;=?\!ZG)P>S``
M46`!BJA[C4@%&T`!&<$`0K`'=!``VO98F3A?6;=J:I``5%`#"@`!0?,'I#%>
M$D$WQU`E!:!_;2`&[60`%&`$>0"+BN8HDU4%9U`N<U``FS0!(XAR!S`"[S<"
M+E!L7=@UA)(316`-!B``-K9V:%A:5*`#!6@-(*`:02(DO&@;"8,,A+`#1+9+
M!7`!1$F42W"4,54(D^)Z5$".'/(%;E!(3@`P:Z$$['A>GT4%T"@,2G``^L-=
M=S8OU?!90,!F!G(`:E"&1'![`VE)NJ$N:N$`","07[`V.0`&/A!W#8`&54`6
M3#@%9'`^@[=10H!NV,4!&(8'3G``9*#_.0+"'K;@,<:A93)08Y)7!&2D`SH@
M`@A0`@3'"#EA21P2:NC&.=>@5&U`!0G@`6;0FJVI`JET!R[P15L7B$+P/P90
M`.=(!0@`?=Y@E6,03R8!1[6UE;8``IET!6D438&I`"&`=5TB%1Q0`T,XE6TG
M9(60*9R(`+6E`G6Y%U62`A/Y&&0!BU40417T:R/``O95$H@Y`#I`!#%88HHP
M><C@!Q>0`'C`28]`1C/I`0A`!L82(CLC'=(S+%AU.@B0FE300@O$0&5@2FHP
MFUY1F]LE!%<"`6*P`?@F=?/V,A<@1RL0$0:P`CV@E4&S"B`@2C@0?/V#*R6P
M`J6TB1B!EO`Y_P*,N1=88B.W4`!`0`5[4)>&I0!SX`5YD`46DBTN804V``8?
M4*+Z-`$=HPM%\)X'Q9A*8)"&(!40(9?ZV0,78!P*4`$#D&$"@"=941*%0'`K
MF0$98`$N0"F%L*!`H(*%<Z?*,P$%P`%?5`0LH%UC@*&"()`G4`91R@$T<7UF
M%`(DN@+%F5O3P0$3`'518&4,``7ZV&;340$)H`,>L(NQ9!XMX@<&4`$ML%$V
M=)_?4`(TD`91PBU-\1,8$(D><`4=X%Z?B4).,(0\4)*A)AJFJ``"T*EM<`+"
MT))E2@<3\`%D4']?0@C2X0<N@`5:H`9#0%?&U`9`8`;/LS5*PP%*@_^='/*G
MW"6HB;.B$W!:V#2"(#"7"<"H6/FH')8#$;`97X!P+2!U)``%)AI/(M$'E"(!
M#T<%0'`"\[1G/>@F;<0"U$D%;A`T?E$$'G-[`#"150!PW:($",!'1.!B)7!"
M#+`"#&D!,W&'0Z($.>$`!K`!A<0#%B`2)2`$^M<#=\`"0P,@Q/@'QN('#)M:
M`K`9<ZI=NM@>Y8`GXNJG@(JAB;(*2*`&0X@#+%`""G`!+?"N6H%>6KE(;H(N
M$'`"*G!&"`8#*Y``97E%1'-[&5!D`]`_.@,<V'DG(V&5SG4%(5`(2?0'<_`"
M$PE^D]4``,`!F=8!`@`"<,ES'^""0R@`*,?_&XM@#?\@!NYW!=JF:DBPACT0
M!;TI;T+1'#M@"RS@!C(0``+0N84@`-K5AO<!&[R2L^-JF\&CN1]P`D#0`RV@
M!R0``1?0`5S&"%C[B,9`'K1&1G2F`@)``L]9EH^55S3A`B,`>5^'&Z!B#N]Q
M=N-D9_,!7TWP`#Y@`A"&04>0MCTP`D@@;S.5.!F@!70P`.);&:]A'+`E`!U`
M@(.&#`YP`!.P![]T![*F!$9S.@SXN:$K`!PRI]H:!2ZP>,GQ+WU*KD!@KG'C
M!R20KF.@A=>W!SH0`KS[3EE+%.3!&I+X2SR0`2&P?\L:$;N"F;I)MA40IY"`
MG?3J`!R``.>8;RRP_R?'``(4X`489"$H4$978+LJ>5V860%\1`?TD[.U(&`G
M4`,$JP5@)1T.D0$>T`(]X`%2.EIZ1@A^(0&?VP9U@`#3,J>_"+7S@1%$LL!)
M>R7"T"5*8`%.T`$AQ@(7H`(M,`$9_(F^VT;(P+]3B[\JR`,Z4,>/!2S_(F?C
M!*`<<"_-$8]"P%(#8&<,<Q'H-@.&ED$/X`$]H`)+\%CK-RU%8`#MUT=ND%#$
M$00N4`%`\'YZX#T&85%D-`8#T`)VY@*9I8A(\;ECT`8!VH5_H'$;A02UD"-'
M2ZZ!"ARGP0@"=@$$)0.K\XD8C)5XO$B,4!CE4`('(+()4`97$,C+.A)"`?^`
M4ZL",G`%.#`$%)!#,?(U&;`!VM4"(2`&*W<1$8",8,`&28H&\>L$%.@)Y^(7
M$2"I8$8'6/`%L>23,.()!_`^99J.84>(YP,!7T"&`]`#6M";U1`CD18!G]L!
M`8``1T/`[%7#,)(II`()K0L$Q0H<$;`#KD(&+##""1`%/.#,&3P&["8/0I8,
M1=`$3]<#\%G'GV0Q?<`!!5`&9A0`*\`"#G!LS@);Q]15X<L"T$()%,`'>HD&
M5R!H5[0(`^0&Z9L`=8`YCP8M)_8S)[`"BX4'6C`$G"4@.[`$6(`'.H`'>S`!
M7P`#4*,7(N$`%F`'5,#,4$""+CD`P1AO,1(MO/+_@`[``AZ`TH+*N+>2`V*@
M!3X->77,")X%9A-``0J0*HR'`*Y6AC(P`50G'[KQ`:<<H3)`!_PU6$G#`B*,
M`[_4`C5@L%(3"7U``&D0=UB]`"^[,X-P8DO<`5TE`A.0`9E##B2`!'/<!E?0
M`B*PIUXC(!"00C40H?OG!GJ`!-"C.>U$`K?XW`)`-X7P/OGJ7DV=WJOX)Q!`
M!D@0=&WPV-E9)?!;I@,P1QF<OBMHVGLV'BZ@!^BW2\NZDL/Q#S&L!<'956U0
M`R,P`EK4!O6X!TZ`6^B&G<!`!F>PV_A<`8\&W'MF`!:P`BVT!WO@`36P`2O@
M!",0!4:]2_R%9Z\C($>S_]Q^1<6T:^(H/@%/I0:&FLM@+'.",`0>4&Y$X`1.
M,%5(O@'''7;`\H%@%J@>`MGN`@'WM$D#$`#/;`!ZH`(!H`<&,*"'T*8C$``!
M('Q7)DN<HP0<(`0K@`,_2@6LQ$HRT`%M0`0"8`$4]SV4X`<JQP<^@`8+L,G@
M<A%2BP3(M0<MU5*[M.@M8`8A<`)XQLD]4J^;D5A$@'Y^]-RDIU%4W*"U]P^E
M*P)G1`==M4N;M.@RH&%A5WSN#69EL`3&(>5N)I!JF$MM8,>-8#MZ8'LF6PL2
M($H;8.2*.RYH7B\W-005X`0XL$M^5`=8(`!?H`#1`@-MN^=0X`!,\.=2,`-Z
MY?]%P1W8,J9"3N`!^^-+,L`#>C`$1'=L=Y(1,GX9$+$#<DRM9O37H<OLZ(X`
M8O#1A(``4;!+9$[FJ+[H(B`$WVQ?C"T"6O`#B=/K;%(L$W!`5CP>-FD2_+VE
M<=)C/^@KZT0H$*``8A#RT+,9NU(">34J\7(T#(`"/J`!88?RN#TLL'T!0[`$
M/\#MJ`$MH8$CB9`O$E`L$+`$0U``1)\"0Y`!''`T6VL($7`U)``#U)4U'##U
M4Y\Y$5`$02,!#.`"+I`YQN"_`</%0U\`2Z`;K`X?.GH1GC`O'')QX<$C#A(D
M\S+WML%(>H$1RT4@$S9:4AN%@(,5X943\X)B2&%LG>O_"47'\SVHIGA_C&C8
M3F5C)OQ+?M*[,Q05`3`P]YH_]V1S]0R@&"=V-0`(&V6<+TX/$)[1-;SR*Z^Q
M]O,,'>#1@W6A%UVJ+JNP$AF/;(<2+W5C#I'V/1:.+(&?D[>_"O-B(R"`LH`3
M'ZRG(HJ-71\0/0"(%'"K.(.`7?+V29NO^9O19GJ1:D=3='Y1"PRXTB4Q*8)P
M5:GV(SV('K>/(]+((#QR]\:P)"5A_Q95#A#BX7L""$H."D5^($4..45_C(V-
M?DHY.7Y%$@Y%F!\@(!^:F(*.?HY_HGZFG4I%?4H?#`R='PJNE8I]HPP.J9N[
MO)L1$(60$D6"2I9%.:.3A62%_X42C)4,JK2CCCL[?9NB18>VC4%!.W\[$!#B
MY-CA.1(1[A'0UO*-?1\.$46HA0[SC!+_^39IPD8P6PXR[APELY9#7)!_.?J4
M("-!4I`(,,R!F*1I5(02$105'%ENQZ%A$I0P.*DH7J-)(/KD4,(J1X1^.'/J
MW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K6+-JW<JU*U)3ID@!
M]<-/ZZ(_A;RJ_1I,[-JW<./F%$65KMR[7^WNI)0V:M]1E/3B'=QODA\*,WI2
M0GSVJ1\#"MPV4C"#PI^%A(-24J!@D($Y@PHIH93#P#(%D!T,XJQ:P6/.G4,7
M(32'C/^!+E":-)GM`"P_U6E5W^,RPY)J4XAXV_.,W+4$,A3\!$'K@$()S@:*
M$*@.9O8^3`ZX4"`3N7%FGH=7S_E#)O0<UKU3^^G,>1B%['.\O__C`#0B`]$I
MT,034%#``"&%<(;)?H6`-A$78+1G0&]^*"+<>\TP,-\?KBD`W1\4$))("=DA
M`D`.K>5G0':=,?$>:N<!I00%6[SP0@H$H(#"%@!H`$8<;,RQA7``//!`''/0
M@,(#&+Q0(P!)+DG`%#ZDD`(*+X"1PA%G:("!D"^@8(`7-J+@P(1SQ($"'TPD
ML:,7,\RQ)@$:\.&%DB\\X`4?E0'P@A<Y`+"%%Q30\.<<&!C_P`0;&J2!(P$Q
MR/$"%TR@$`<%3!#PYPSFQ3@790!`R@<7;!CP@)<$/```!5.H-@<;,V#`1PQ\
M&```$W$0,`,;&`#P00I>3`%`=3%XP008!&*`P18IS#&%!B@`4$0*%,PV@P]S
M:*!!$L/*H0%G&@3[@`%;8$"`%U#$`,!G!/A``0`S])?"#%O,P(4!&LBQJP(Q
MQ,!&#)"M""\`8&R1GV">]C,?!1A00`";=OH`!0!=8)"$N60][("F&*2QQ:EQ
M%$&CGSK*@0$8,/A9)05/E!"#K!K\P<25*82WW7P/].<%%P08@$(*7'R,@@9L
M./``8AA<1\.Y6SC*1&DQ//""#V#<_ZL!#6!H,$>_/B"HP18^S`"OJG\EG%,1
M<S#A\*@:?%;""VQP04/<@X"!`K\/Q!"R:GQ<PJP&ERB0J=@I:]#$&25PT04?
M&OBA00K,%N$EAQ3$X<<,J#KP,PU^,R$M"F1`D80$!GB[J@],:&`M$Z[-D(0#
M7[]K0+]Q$(*!'`H00$##"LQ=EMEG(^IP'$R\$&()^<;*!VJJ>?$X'ZG.,8<!
M<5PR]`,*4+`Q!10T>^,!4X#!!!<``*``HUNHSC.">;RK0:::3\'&M$.O.Z3K
MY,GQ,AAI*&#P?$.:2,Y2\`(R]`U24V`"[&@P`Q30*4170ACPK$&6>,VA9@"(
ME@-B4+-]/?^F"&"@@1<>D"T4R(%\(2).\0RFJU>A8`H`\T(*F!`#/[!!@YFZ
M'&@<,(,XB!`,!*"`$KP$+0"DH&H&2($22@"&7&B`"RA@@QP<L"P:S,%/*8`!
MY)RG`!F"80XSD`,*.!A%1-E-?Y&9($Z0LYE!K$8!._R,&\$@/AK`9S7`F<V$
MA%.($"F@0#"X#FK`>"9*`(<"9NI,"?+AQAE`9X\&2,4P!`%'X7P&#)R9@0'(
M($A,'&9%JNF.=LA""%TA0HTYX0==CO.).=#D$IZ!EOXN@8D$(8@L9^H0/]IS
M@.D%\A(3PD2)DO,N!^!B&(OP#&NX\0$E_($F?P#E)M%$@3Y`1@(0,*!E@GHC
,HD6X!CR7,$4@```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
